{"entity":{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","aka":[],"tldr":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu.","summary":"HER2-positive breast cancer (15-20% of cases; HER2 IHC 3+ or ISH-amplified) was the most aggressive subtype until trastuzumab (1998) made it one of the most treatable. The modern curative pathway is response-adapted: neoadjuvant chemotherapy with dual HER2 blockade (or, since 2026, T-DXd followed by THP), surgery, then either antibody completion for patients with a pathologic complete response or an ADC for residual disease (T-DM1 from KATHERINE, now T-DXd from DESTINY-Breast05). Small node-negative tumours are cured with paclitaxel-trastuzumab alone; PHERGain showed that an early PET response can spare a third of patients chemotherapy altogether. Extended adjuvant neratinib and adjuvant pertuzumab add small gains in higher-risk, node-positive disease.\n\nMetastatic disease has been transformed twice: by CLEOPATRA's pertuzumab (OS 57 months) and then by trastuzumab deruxtecan, which beat T-DM1 by a wide margin in second line (DESTINY-Breast03) and beat THP in first line (DESTINY-Breast09, PFS 40.7 months; approved 2025). Brain metastases, which develop in up to half of patients, are now treatable systemically with tucatinib (HER2CLIMB) and T-DXd (DESTINY-Breast12). HER2CLIMB-05 (tucatinib maintenance) and PATINA (palbociclib maintenance in HR+/HER2+, approved 2026) intensify chemotherapy-free maintenance, and a wave of Chinese HER2 ADCs (trastuzumab rezetecan, BL-M07D1, ARX788, disitamab vedotin) is producing Enhertu-scale results.\n\nOpen problems are the sequencing of HER2 ADCs after T-DXd (payload cross-resistance), interstitial lung disease, cardiotoxicity across years of therapy, the cost and duration of antibody therapy, brain metastases prevention, and de-escalation: identifying the substantial fraction of patients who are over-treated. The pipeline is defined by T-DXd's move into every curative setting, tucatinib-based maintenance, next-generation and biparatopic HER2 ADCs (zanidatamab zovodotin), HER2 CAR-T and vaccines, and imaging- and ctDNA-adapted de-escalation trials.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/HER2-positive_breast_cancer","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/HER2-positive_breast_cancer"}],"tags":["breast","spike"],"related":[],"indications":[],"sections":[],"technologies":["her2-pet","fdg-pet","site-specific-conjugation"],"targets":["her2"],"drugs":[],"companies":["astrazeneca","pfizer","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["phergain"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"group":"breast","burden":"15-20% of breast cancers (roughly 400,000 cases per year worldwide). Ten-year survival for early-stage disease treated with trastuzumab-based therapy exceeds 80%.","subtypes":["HER2-enriched (PAM50; highest pCR rates to HER2 blockade)","HR+/HER2+ ('triple-positive', ~50% of HER2+; lower pCR, endocrine therapy and CDK4/6 maintenance relevant)","HR-/HER2+ (higher pCR, more relapse in first 3 years)","HER2-mutant (activating mutations without amplification; T-DXd tumour-agnostic, HER2 TKIs; more common in lobular and HER2-low)","HER2 heterogeneous tumours (mixed amplified and non-amplified clones; lower pCR)","Small node-negative (stage I) disease cured by de-escalated therapy"],"biomarkers":["HER2 IHC 3+ or ISH-amplified","HR status","pCR after neoadjuvant therapy","HER2 IHC 3+ or IHC 2+ with ISH amplification (ASCO/CAP 2018 criteria); HER2 heterogeneity","HR status (drives triple-positive management, PATINA eligibility)","Pathologic complete response after neoadjuvant therapy (selects T-DM1/T-DXd post-neoadjuvant)","Early FDG-PET response (PHERGain de-escalation)","LVEF by echocardiography or MUGA every 3 months on anti-HER2 therapy","Brain MRI when symptomatic; surveillance MRI debated","HER2 status on re-biopsy at progression (conversion in 10-15%)","PIK3CA mutation (lower pCR; INAVO122 tests inavolisib in HER2+)","ctDNA MRD (investigational for post-neoadjuvant escalation)"],"standardOfCare":[{"setting":"Early stage","approach":"Neoadjuvant THP or T-DXd → surgery → trastuzumab/pertuzumab (pCR) or T-DXd/T-DM1 (residual).","refs":[],"guideline":{"nccn":"Category 1, preferred: neoadjuvant pertuzumab + trastuzumab + chemotherapy; adjuvant trastuzumab; T-DM1 for residual disease Category 1","esmoMcbs":"A (KATHERINE); A (HERA); C (NeoSphere, APHINITY)","version":"NCCN Guidelines: Breast Cancer","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13114725/"}},{"setting":"Metastatic","approach":"T-DXd + pertuzumab first line (DESTINY-Breast09); tucatinib + trastuzumab + capecitabine for brain metastases; palbociclib maintenance if HR+.","refs":[],"guideline":{"esmoMcbs":"4 (DESTINY-Breast03); 4 (CLEOPATRA); 4 (HER2CLIMB)","version":"NCCN Guidelines: Breast Cancer","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13114725/"}},{"setting":"Stage I (≤2-3 cm, node-negative)","approach":"Surgery then weekly paclitaxel × 12 + trastuzumab × 1 year (APT); T-DM1 × 17 cycles is an alternative (ATEMPT). Endocrine therapy if HR+.","refs":[],"guideline":{"nccn":"2A","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Stage II-III, neoadjuvant","approach":"TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) or anthracycline-taxane + HP; from 2026, T-DXd × 4 → THP (DESTINY-Breast11, pCR 67%). PET-adapted chemotherapy omission (PHERGain) in trials.","refs":["phergain"],"guideline":{"nccn":"1","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Post-neoadjuvant, pathologic complete response","approach":"Complete 1 year of trastuzumab (± pertuzumab if node-positive at diagnosis); endocrine therapy if HR+; radiation per stage.","refs":[],"guideline":{"nccn":"1","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Post-neoadjuvant, residual invasive disease","approach":"T-DXd (DESTINY-Breast05, iDFS HR 0.47 vs T-DM1; approved 2026) replacing T-DM1 (KATHERINE); consider extended adjuvant neratinib for HR+ high-risk.","refs":[],"guideline":{"nccn":"1 (T-DM1); T-DXd pending update","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Adjuvant (upfront surgery), node-positive","approach":"Chemotherapy + trastuzumab + pertuzumab for 1 year (APHINITY); trastuzumab alone for lower risk; 6 months acceptable where resources are limited (PERSEPHONE).","refs":[],"guideline":{"nccn":"1","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Metastatic, first line","approach":"T-DXd + pertuzumab (DESTINY-Breast09, PFS 40.7 months; approved 2025) or taxane + trastuzumab + pertuzumab (CLEOPATRA) followed by maintenance: HP ± tucatinib (HER2CLIMB-05) and, if HR+, endocrine therapy + palbociclib (PATINA, approved 2026).","refs":[],"guideline":{"nccn":"1, preferred (T-DXd + pertuzumab)","esmoMcbs":"4 (CLEOPATRA)","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Metastatic, second line","approach":"T-DXd if not used first line (DESTINY-Breast03, PFS HR 0.33 vs T-DM1); tucatinib + trastuzumab + capecitabine, especially with brain metastases (HER2CLIMB).","refs":[],"guideline":{"nccn":"1","esmoMcbs":"4 (DESTINY-Breast03)","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Metastatic, later lines","approach":"T-DM1; neratinib or lapatinib + capecitabine; margetuximab + chemotherapy; trastuzumab + chemotherapy (continued HER2 blockade); zanidatamab and Chinese ADCs (trastuzumab rezetecan, disitamab vedotin) where available; trials.","refs":[],"guideline":{"nccn":"2A","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Brain metastases","approach":"Systemic: tucatinib triplet or T-DXd (DESTINY-Breast12, intracranial ORR 72%); local: stereotactic radiosurgery or surgery for symptomatic or large lesions; whole-brain RT reserved.","refs":[],"guideline":{"nccn":"1 (tucatinib triplet)","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"}},{"setting":"Cardiac monitoring and survivorship","approach":"LVEF every 3 months during anti-HER2 therapy; hold and cardioprotect for declines; anthracycline-free regimens preferred; long-term surveillance for late recurrence in HR+/HER2+.","refs":[]}],"stateOfArt":["T-DXd across the disease continuum.","Chemotherapy de-escalation guided by early response.","Ten-year survival above 80% for early disease: the subtype with the poorest outlook in the 1990s is now one of the most treatable.","Response-adapted curative therapy: pCR patients de-escalate, residual disease escalates to an ADC (now T-DXd, iDFS HR 0.47 vs T-DM1).","T-DXd across the continuum: neoadjuvant (2026), post-neoadjuvant (2026), first-line metastatic with pertuzumab (2025, PFS 40.7 months), second line, and brain metastases.","Systemic control of brain metastases (tucatinib, T-DXd) allowing deferral of radiation.","Chemotherapy-free maintenance intensification: tucatinib (HER2CLIMB-05) and palbociclib for HR+/HER2+ (PATINA).","Chemotherapy omission for a third of patients using early PET response (PHERGain)."],"history":[{"year":1987,"title":"Slamon shows HER2 amplification marks aggressive disease, and a drug target","refs":[]},{"year":1987,"title":"Slamon shows HER2 amplification marks aggressive disease, and a drug target","note":"Science paper identifying HER2/neu amplification in 25-30% of breast cancers.","refs":["her2"]},{"year":1998,"title":"Trastuzumab approved","refs":[]},{"year":1998,"title":"Trastuzumab approved for metastatic disease","note":"First antibody for a solid tumour; OS benefit with chemotherapy.","refs":[]},{"year":2005,"title":"Adjuvant trastuzumab halves recurrence (HERA, B-31/N9831)","refs":[]},{"year":2007,"title":"Lapatinib: first HER2 pill","refs":[]},{"year":2012,"title":"Pertuzumab and dual blockade (CLEOPATRA)","refs":[]},{"year":2013,"title":"First solid-tumour ADC: T-DM1","refs":[]},{"year":2013,"title":"T-DM1: first solid-tumour ADC; pertuzumab first pCR-based approval","refs":[]},{"year":2015,"title":"APT: de-escalation for small tumours","refs":[]},{"year":2017,"title":"First trastuzumab biosimilar; neratinib; APHINITY","refs":[]},{"year":2018,"title":"KATHERINE: T-DM1 for residual disease","refs":[]},{"year":2019,"title":"T-DXd approved; HER2CLIMB proves CNS benefit","refs":[]},{"year":2020,"title":"Tucatinib, margetuximab, Phesgo approved","refs":[]},{"year":2021,"title":"T-DXd beats T-DM1 (DESTINY-Breast03)","refs":[]},{"year":2021,"title":"DESTINY-Breast03: T-DXd beats T-DM1","refs":[]},{"year":2024,"title":"PHERGain chemotherapy omission; DESTINY-Breast12 brain metastases; zanidatamab approved (BTC)","refs":["phergain"]},{"year":2025,"title":"DESTINY-Breast09 first-line approval; DESTINY-Breast05 and HER2CLIMB-05 positive; trastuzumab rezetecan approved (China, NSCLC)","refs":[]},{"year":2026,"title":"T-DXd approved in early-stage disease","refs":[]},{"year":2026,"title":"T-DXd approved neoadjuvant and post-neoadjuvant; palbociclib maintenance for HR+/HER2+ (PATINA)","refs":[]}],"pipeline":["her2-pet","phergain"],"openProblems":["Brain metastases in ~50% of metastatic patients.","Which patients can skip chemotherapy entirely.","Sequencing after T-DXd: no randomised data on which HER2 ADC or TKI works after TOP1-payload failure.","Interstitial lung disease with T-DXd in curative settings, where patients would otherwise be cured.","Over-treatment: which patients need pertuzumab, a full year of antibodies, or any chemotherapy at all (PHERGain-2, response-adapted trials).","Brain metastasis prevention and whether systemic-first strategies preserve cognition.","HR+/HER2+ ('triple-positive') disease: optimal integration of endocrine therapy, CDK4/6 inhibitors, and HER2 blockade.","Cardiotoxicity surveillance burden versus event rates in low-risk patients.","Global access: biosimilars have widened trastuzumab access but pertuzumab, T-DM1, and T-DXd remain unavailable in much of the world.","HER2 heterogeneity and HER2 conversion at relapse require re-biopsy strategies or HER2 PET."]},"route":"/indications/breast-her2-positive/","neighbours":{"technology":[{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"},{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/"}],"trial":[{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"f-18-fluorothymidine","kind":"drug","name":"Fluorothymidine F-18 (FLT)","route":"/drugs/f-18-fluorothymidine/"}],"institution":[{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/"},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/"}],"bottleneck":[{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/"}]}}